A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC)

A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC)

This phase III study is the first study to demonstrate the superiority of new oral fluoropyrimidine S-1 over tegafur–uracil as adjuvant chemotherapy for stage II/III rectal cancer patients with no preoperative treatment in terms of relapse-free survival. S-1 can be considered an important option, es...

Full description

Bibliographic Details
Main Authors: Oki, E., Murata, A., Yoshida, K., Maeda, K., Ikejiri, K., Munemoto, Y., Sasaki, K., Matsuda, C., Kotake, M., Suenaga, T., Matsuda, H., Emi, Y., Kakeji, Y., Baba, H., Hamada, C., Saji, S., Maehara, Y.
Format: Online
Language:English
Published: Oxford University Press 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922318/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922318/

Similar Items